Today: 19 April 2026
BT Group share price edges higher after Monday slide as market eyes Feb 5 update
27 January 2026
1 min read

BT Group share price edges higher after Monday slide as market eyes Feb 5 update

London, Jan 27, 2026, 09:40 GMT — Regular session

  • BT shares nudged 0.1% higher to about 183p in early London trading, clawing back some ground after dropping 2.9% on Monday
  • Focus shifts to BT’s trading update due Feb 5, coinciding with the Bank of England’s rate decision set for the same day
  • The interim dividend is set for payment on Feb 11

BT Group shares nudged higher in early London trading Tuesday, recovering a bit from Monday’s drop. At 09:40 GMT, the stock stood at 183.05 pence, up 0.14%, valuing BT at about £17.8 billion. Vodafone, on the other hand, dipped 0.5%.

This change matters because BT is gearing up for a busy stretch, with a trading update due on Feb. 5 and its interim dividend payment scheduled for Feb. 11.

February 5 brings the next Bank of England policy meeting. According to a Reuters survey, economists expect the central bank to hold its benchmark rate at 3.75%.

BT recovered some ground following Monday’s steep decline that saw shares close at 182.80 pence, down 2.9% on roughly 26 million shares changing hands. Tuesday’s trading was quieter, with the stock drifting between 182.2 and 184.1 pence.

Traders aren’t sweating the slight uptick as much as BT’s broadband future — will the company keep its customers despite fierce discounting and bundling from rivals? The key question also hangs on whether the fibre rollout keeps fueling cash flow.

In its latest update, Chief Executive Allison Kirkby assured investors that BT remains “on track” to hit its financial targets for the year. Investegate

BT declared an interim dividend of 2.45 pence per share for the half-year, with payment slated for Feb. 11. The ex-dividend date will be Dec. 29, the company confirmed.

Openreach, the network arm of BT, still holds a crucial role. It’s been shifting customers to full-fibre broadband — fibre-to-the-premises (FTTP), where fibre optic cables connect straight to homes and offices. The goal: cover 25 million premises by December 2026.

That said, the setup cuts both ways. If Openreach line losses pick up or fibre rollout hits a snag, the market could quickly turn against a stock prized for steady cash flow—especially as rate-cut prospects remain uncertain.

BT is set to deliver its next detailed update on Feb. 5. Investors will zero in on Openreach volumes, the pace of fibre rollout, and any changes to the company’s cash flow forecast.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Previous Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

Micron stock jumps in premarket on $24B Singapore fab plan as AI memory crunch tightens
Next Story

Micron stock jumps in premarket on $24B Singapore fab plan as AI memory crunch tightens

Go toTop